Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working PartyGerrit Jan Schuurhuis, Gert J. Ossenkoppele, Jeffrey L. Jorgensen et al.|Blood|2018Cited by 1k
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working PartyMichael Heuser, Jacqueline Cloos, Sylvie Freeman et al.|Blood|2021Cited by 714
In Silico Analysis of Kinase Expression Identifies WEE1 as a Gatekeeper against Mitotic Catastrophe in GlioblastomaShahryar E. Mir, Thomas Würdinger, Philip C. De Witt Hamer et al.|Cancer Cell|2010Cited by 293
Clinical Impact of Additional Cytogenetic Aberrations, <i>cKIT</i> and <i>RAS</i> Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study GroupKim Klein, Brenda Gibson, Gertjan J.L. Kaspers et al.|Journal of Clinical Oncology|2015Cited by 92
2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working PartyJacqueline Cloos, Michael Heuser, Peter J.M. Valk et al.|Blood|2025Cited by 22